Formulary Item Restrictions and/or Advice Site availability

Size: px
Start display at page:

Download "Formulary Item Restrictions and/or Advice Site availability"

Transcription

1 Formulary Item Restrictions and/or Advice Site availability C&W CNWL Typical Antipsychotic drugs Chlorpromazine 25mg Chlorpromazine 50mg Chlorpromazine 100mg Chlorpromazine 25mg/5ml syrup Chlorpromazine 100mg/5ml syrup Chlorpromazine: If IM administration is necessary, haloperidol is preferred. Chlorpromazine is irritant and may cause hypotension and tachycardia BP should be monitored for 30 mins after IM. Not licensed for IV use; should not be used IV IM doses are lower than equivalent There is no convincing evidence that Approximate equivalent doses of Advice of Royal College of Chlorpromazine 25mg/ml Flupentixol 3mg Haloperidol 500mcg capsule Haloperidol 1.5mg Haloperidol 5mg Haloperidol 10mg Haloperidol 2mg/ml liquid Haloperidol 5mg/ml IM doses are lower than equivalent There is no convincing evidence that Approximate equivalent doses of Advice of Royal College of

2 Levomepromazine 25mg Levomepromazine 25mg/ml IM doses are lower than equivalent There is no convincing evidence that Approximate equivalent doses of Advice of Royal College of Pimozide 4mg Prochlorperazine 5mg Prochlorperazine 5mg/5ml syrup Prochlorperazine 25mg suppository Prochlorperazine 12.5mg/ml Promazine 25mg Promazine 25mg/5ml oral solution Sulpiride 200mg Sulpiride 400mg Sulpiride 200mg/5ml SF oral suspension Trifluoperazine 1mg Trifluoperazine 5mg Trifluoperazine 5mg/5ml oral liquid Trifluoperazine 10mg SR capsule Trifluoperazine 15mg SR capsule IM doses are lower than equivalent There is no convincing evidence that Approximate equivalent doses of Advice of Royal College of

3 Zuclopenthixol dihydrochloride 10mg Zuclopenthixol dihydrochloride 25mg Zuclopenthixol acetate 50mg/ml Zuclopenthixol acetate 100mg/2ml (Clopixol Acuphase ) Atypical Antipsychotics Amisulpride 50mg Amisulpride 200mg Amisulpride 400mg Amisulpride 100mg/ml solution Atypical antipsychotics: Extrapyramidal symptoms and No evidence supporting use in No evidence supporting prn use of There is no convincing evidence that Approximate equivalent doses of Advice of Royal College of

4 Aripiprazole 5mg Aripiprazole 10mg Aripiprazole 10mg orodispersible Aripiprazole 15mg Aripiprazole 15mg orodispersible Aripiprazole 7.5mg/ml (1.3-ml (9.75- mg) vial) Clozapine 25mg Clozapine 100mg (Zaponex ) Atypical antipsychotics: Extrapyramidal symptoms and No evidence supporting use in No evidence supporting prn use of IM doses are lower than equivalent There is no convincing evidence that Approximate equivalent doses of Advice of Royal College of Atypical antipsychotics: Extrapyramidal symptoms and No evidence supporting use in No evidence supporting prn use of Registration with the Zaponex Treatment Access System (Ztas) and routine blood counts are required due to the risk of agranulocytosis

5 Olanzapine 2.5mg Olanzapine 5mg Olanzapine 7.5mg Olanzapine 10mg Olanzapine 15mg Olanzapine 20mg Olanzapine 5mg orodispersible Olanzapine 10mg orodispersible Olanzapine 15mg orodispersible Olanzapine 20mg orodispersible Olanzapine 10mg Quetiapine 25mg Quetiapine 100mg Quetiapine 150mg Quetiapine 200mg Quetiapine 300mg Quetiapine 50mg M/R Quetiapine 200mg M/R Quetiapine 300mg M/R Quetiapine 400mg M/R Atypical antipsychotics: Extrapyramidal symptoms and No evidence supporting use in No evidence supporting prn use of IM doses are lower than equivalent There is no convincing evidence that Approximate equivalent doses of Advice of Royal College of Atypical antipsychotics: Extrapyramidal symptoms and No evidence supporting use in No evidence supporting prn use of There is no convincing evidence that Approximate equivalent doses of Advice of Royal College of

6 Risperidone 500mcg Risperidone 1mg Risperidone 2mg Risperidone 3mg Risperidone 4mg Risperidone 6mg Risperidone 3mg orodispersible Risperidone 4mg orodispersible Risperidone 1mg/ml liquid Risperidone 1mg orodispersible Risperidone 2mg orodispersible Atypical antipsychotics: Extrapyramidal symptoms and No evidence supporting use in No evidence supporting prn use of There is no convincing evidence that Approximate equivalent doses of Advice of Royal College of chlorpromazine/day) see BNF Antipsychotic depot s - typicals 20mg/ml 100mg/ml 200mg/ml 40mg/2ml 50mg/0.5ml 100mg/ml 25mg/ml 12.5mg/0.5ml 50mg/0.5ml Haloperidol decanoate 50mg/ml Haloperidol decanoate 100mg/ml Pipotiazine palmitate 50mg/ml Pipotiazine palmitate 100mg/2ml

7 Zuclopenthixol decanoate 200mg/ml Zuclopenthixol decanoate 500mg/ml Antipsychotic depot s - atypicals Risperidone 25mg depot Risperidone 37.5mg depot Risperidone 50mg Antimanic drugs Valproic acid 250mg EC Lithium carbonate 200mg SR Lithium carbonate 250mg Lithium carbonate 400mg MR Lithium citrate (Li-Liquid) 509mg/5ml Lithium citrate (Priadel) 520mg/5ml Mental Health Trust Only Preparations vary widely in bioavailability; changing the preparation requires the same precautions as initiation of treatment Note: Lithium carbonate 200mg lithium citrate 509mg

Chapter 4 ~ Central nervous system

Chapter 4 ~ Central nervous system Chapter 4 ~ Central Nervous System: Special Section 1 of 5 Chapter 4 ~ Central nervous system 4.1 Hypnotics and anxiolytics 4.1.1 Hypnotics LOPRAZOLAM Tablet 1mg LORMETAZEPAM Tablet 500microgram PROMETHAZINE

More information

South London and the Maudsley NHS Foundation Trust Medicines Formulary

South London and the Maudsley NHS Foundation Trust Medicines Formulary South London and the Maudsley NHS Foundation Trust Medicines Formulary Medicine Formulations Restrictions Additional Information / Related NICE Technology Appraisal 4.1 Hypnotics and anxiolytics 4.1.1

More information

Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses

Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses Preferred Prescribing Choices of Antipsychotic Drugs (APD) in Adults for Schizophrenia and Other Psychoses HPFT Medicines Formulary lists the APDs that have been approved for use, however, it does not

More information

Mental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service

Mental Health Medicines Management Pilot. Community Pharmacy. High Dose Antipsychotic Screening, Education & Advice Service Mental Health Medicines Management Pilot Community Pharmacy High Dose Antipsychotic Screening, Education & Advice Service Approved Version 1 Date of First Issue Review Date Date of Issue Author / Contact

More information

Medicines Formulary BNF Section 4 Central Nervous System

Medicines Formulary BNF Section 4 Central Nervous System Medicines BNF Section 4 4.1 Hypnotics and anxiolytics Chloral Hydrate 500mg/5ml Solution Clomethiazole 192mg Capsules Lormetazepam Tablets Melatonin Capsules Nitrazepam Suspension Nitrazepam Tablets Temazepam

More information

Antipsychotics. BMF 84 - Antipsychotics

Antipsychotics. BMF 84 - Antipsychotics Antipsychotics BMF 84 - Antipsychotics Antipsychotic medications (neuroleptics) are used for the treatment of psychosis, mainly schizophrenia and manic depression (bipolar disorder). They reduce symptoms

More information

SHARED CARE GUIDELINE

SHARED CARE GUIDELINE SHARED CARE GUIDELINE Title: Prescribing and/ or Monitoring of Antipsychotics Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside

More information

Document Title Antipsychotics Prescribing Guidelines for Schizophrenia

Document Title Antipsychotics Prescribing Guidelines for Schizophrenia Document Title Antipsychotics Prescribing Guidelines for Schizophrenia Document Description Document Type Prescribing Guidance Service Application Medicines Management Version 1.0 Policy Reference no.

More information

High Dose Antipsychotic Medication Policy

High Dose Antipsychotic Medication Policy High Dose Antipsychotic Medication Policy Policy Title State previous title where relevant State if Policy New or Revised Policy Strand Org, HR, Clinical, H&S, Infection Control, Finance For clinical policies

More information

MMG012 GUIDELINES FOR THE USE OF HIGH DOSE ANTIPSYCHOTIC MEDICATION

MMG012 GUIDELINES FOR THE USE OF HIGH DOSE ANTIPSYCHOTIC MEDICATION MMG012 GUIDELINES FOR THE USE OF HIGH DOSE ANTIPSYCHOTIC MEDICATION Page 1 of 16 Table of Contents Why we need this Policy... 3 What the Policy is trying to do... 3 Which stakeholders have been involved

More information

High Dose Antipsychotic Therapy (HDAT) guideline

High Dose Antipsychotic Therapy (HDAT) guideline Document level: Trustwide (TW) Code: MP18 Issue number: 4 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Authors details Michael Slater (Clinical Pharmacist, tel. 01625

More information

Pharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS

Pharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS Workforce Safety & Insurance Revised Document Date: 07/21/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management

More information

Joint Formulary for Psychotropic Medication.

Joint Formulary for Psychotropic Medication. Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Page 1 Table of Contents Section Page Number Page 2 Definition of categories

More information

This document has been produced in collaboration with the Lancashire Commissioning Support Unit

This document has been produced in collaboration with the Lancashire Commissioning Support Unit Joint for Psychotropic Medication. This document has been produced in collaboration with the Lancashire Commissioning Support Unit Date: December 2014. Reviewed August 2016. Next review Date April 2019

More information

Antipsychotic Prescribing Audit:

Antipsychotic Prescribing Audit: Antipsychotic Prescribing Audit: Measuring the impact of a prescribing intervention Audit Co-ordinator/ Author of Report: Supervisor: Professor Shôn W Lewis Table of Contents List of Tables... 3 List of

More information

High Dose Antipsychotic Therapy (HDAT) guideline

High Dose Antipsychotic Therapy (HDAT) guideline Document level: Trustwide (TW) Code: MP18 Issue number: 2 High Dose Antipsychotic Therapy (HDAT) guideline Lead executive Medical Director Author and contact number Lead Clinical Pharmacist 01625 663 857

More information

Prescription of High Dose Antipsychotic Medication

Prescription of High Dose Antipsychotic Medication Subject (M1) Title Medicine Prescription of High Dose Antipsychotic Medication Manual Mental Health Procedure No M1-P-2-MH Department Pharmacy Distribution All Author Rae McKnight Review 4 Reviewer Jonathan

More information

This factsheet covers:

This factsheet covers: Antipsychotics If you experience psychosis as part of your illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar

More information

Antipsychotics. This factsheet covers -

Antipsychotics. This factsheet covers - Antipsychotics If you experience psychosis as part of an illness, you may be offered antipsychotic medication. Antipsychotics are generally used to treat psychosis, but are also used to treat bipolar disorder

More information

Safe transfer of prescribing guidance

Safe transfer of prescribing guidance Safe transfer of prescribing guidance TEWV Prescriber Summary Application required before prescribing Products requiring an application, before prescribing, using the single application form Unlicensed

More information

AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE

AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE Topic AT RISK MENTAL STATES IN PSYCHOSIS AND SCHIZOPHRENIA IN CHILDREN AND YOUNG PEOPLE Scope 4.3.1 (a) Review question(s)

More information

Treatment of Schizophrenia Appendix Three Page 1 of 8

Treatment of Schizophrenia Appendix Three Page 1 of 8 Prescribing Guidelines Treatment of Schizophrenia Scope of this guidance This guidance aims to describe the pharmacological management of schizophrenia at a simple and intermediate level, with a brief

More information

NHS Grampian Guidance For Staff Working In The Mental Health Service For The Use Of High-Dose Antipsychotic Medication

NHS Grampian Guidance For Staff Working In The Mental Health Service For The Use Of High-Dose Antipsychotic Medication NHS Grampian Westholme Woodend Hospital Queens Road ABERDEEN AB15 6LS Date 20 th November 2014 Our Ref HDAT_MGPG/Nov14 Enquiries to Caroline Hind Extension 56088 Direct Line 01224 556088 Email caroline.hind2@nhs.net

More information

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2016 PQRS OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY

More information

Formulary and Prescribing Guidelines

Formulary and Prescribing Guidelines Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary

More information

Medicines Guideline: High-dose antipsychotic prescribing (MG01)

Medicines Guideline: High-dose antipsychotic prescribing (MG01) Medicines Guideline: High-dose antipsychotic prescribing (MG01) Document author Assured by Review cycle Ben Browning, Locality Lead Pharmacist (Secure Services) MOG sub-group (04.05.16) Review every two

More information

Special Project. National Mental Health Benchmarking Project Forensic Forum. Seclusion Medication Audit

Special Project. National Mental Health Benchmarking Project Forensic Forum. Seclusion Medication Audit National Mental Health Benchmarking Project Forensic Forum Special Project Seclusion Medication Audit A joint Australian, State and Territory Government Initiative October 2007 National Benchmarking Project

More information

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety

Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety Measure #383 (NQF 1879): Adherence to Antipsychotic Medications For Individuals with Schizophrenia National Quality Strategy Domain: Patient Safety 2017 OPTIONS F INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE

More information

Antipsychotic Medication: Monitoring Side Effects

Antipsychotic Medication: Monitoring Side Effects Antipsychotic Medication: Monitoring Side Effects Aims Review national practice guidelines and evidence regarding current standards of care. Discuss clinical implications of AP side effects. Reflect on

More information

FORMULARY AND PRESCRIBING GUIDELINES 2017

FORMULARY AND PRESCRIBING GUIDELINES 2017 FORMULARY AND PRESCRIBING GUIDELINES 2017 1 Document Control Summary Issue Date Amended Section /page Author/ Amended by 1. Sept 06 All Jane Moriba Summary of Change Removed Trust policy and guideline

More information

Guidelines on Choice and Selection of Antipsychotics for the Management of Psychosis and Schizophrenia in Adults

Guidelines on Choice and Selection of Antipsychotics for the Management of Psychosis and Schizophrenia in Adults Working in partnership: Hertfordshire Partnership University NHS Foundation Trust East and North Hertfordshire Clinical Commissioning Group Herts Valleys Clinical Commissioning Group Guidelines on Choice

More information

Slide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics

Slide 1. Slide 2. Slide 3. About this module. About this module. Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Slide 1 Antipsychotics: The Essentials Module 5 A Primer on Selected Antipsychotics Flavio Guzmán, MD Slide 2 About this module 13 antipsychotics will be studied 3 first generation antipsychotics 10 second

More information

Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015

Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A for use in Northern Ireland) Sep 2015 Therapeutic options for adult patients unable to take solid oral dosage forms (Adapted from UKMi Q&A 294.3 for use in Northern Ireland) Sep 2015 BNF 1.3.5 Proton pump inhibitors Lansoprazole orodispersible

More information

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance]

SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA. [compatible with NICE guidance] SiGMA/ MMHSCT GUIDELINES FOR ANTIPSYCHOTIC DRUG TREATMENT OF SCHIZOPHRENIA [compatible with NICE guidance] Medicines Management Committee August 2002 For review August 2003 Rationale The SiGMA algorithm

More information

National Clinical Audit of Psychosis (NCAP) Audit of practice form. Notes for completion

National Clinical Audit of Psychosis (NCAP) Audit of practice form. Notes for completion National Clinical Audit of Psychosis (NCAP) Audit of practice form tes for completion Audit forms should be completed by the psychiatrist accountable for the patient's care If delegated, the psychiatrist

More information

Birmingham and Solihull Mental Health NHS Foundation Trust. Formulary. March 2013

Birmingham and Solihull Mental Health NHS Foundation Trust. Formulary. March 2013 Birmingham and Solihull Mental Health NHS Foundation Trust Formulary March 2013 1 Table of contents Antipsychotics Introduction p3 1. Antipsychotics available p4 2. Mood stabilisers available p5 3. Prescribing

More information

Thorazine 25 Mg Iv chlorpromazine hcl 50 mg chlorpromazine 10 mg chlorpromazine tablets uses chlorpromazine tablets ip 100mg thorazine ivpb

Thorazine 25 Mg Iv chlorpromazine hcl 50 mg chlorpromazine 10 mg chlorpromazine tablets uses chlorpromazine tablets ip 100mg thorazine ivpb Thorazine 25 Mg Iv 1 thorazine cost 2 chlorpromazine thorazine for hiccups 3 chlorpromazine injection dosage 4 recreational thorazine uses 5 chlorpromazine 25 mg/2ml 6 chlorpromazine hcl 50 mg 7 buy chlorpromazine

More information

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services VIOLENCE, AGGRESSION OR SEVERE BEHAVIOURAL DISTURBANCE Introduction During an acute episode or illness, some

More information

Atypical Antipsychotic Use for the Behavioural and Psychological Symptoms of Dementia in the Elderly

Atypical Antipsychotic Use for the Behavioural and Psychological Symptoms of Dementia in the Elderly Overall Comprehensive Research Plan: Atypical Antipsychotic Use for the Behavioural and Psychological Symptoms of Dementia in the Elderly October 9, 2014 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca

More information

GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA)

GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA) GUIDELINES FOR THE USE OF ARIPIPRAZOLE LONG-ACTING INJECTION (ABILIFY MAINTENA) Introduction Aripiprazole long-acting injection (LAI)is licensed for the maintenance treatment of adult patients with schizophrenia

More information

CHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES?

CHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES? CHLORPROMAZINE EQUIVALENTS VERSUS DEFINED DAILY DOSES: HOW TO COMPARE ANTIPSYCHOTIC DRUG DOSES? C.A.W. Rijcken 1, T.B.M. Monster 1, J.R.B.J. Brouwers 1, L.T.W. de Jong van den Berg 1 1 Department of Social

More information

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services

Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services Formulary and Clinical Guideline Document Pharmacy Department Medicines Management Services DRIVING AND MENTAL HEALTH CONDITIONS AND TREATMENTS General information Driving while impaired by a physical

More information

University of Groningen. Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia

University of Groningen. Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia University of Groningen Pharmacy data as a tool for assessing antipsychotic drug use Rijcken, Claudia IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to

More information

ANTIPSYCHOTIC GUIDELINES

ANTIPSYCHOTIC GUIDELINES ANTIPSYCHOTIC GUIDELINES TREATMENT OF SCHIZOPHRENIA AND PSYCHOSIS Page 1 of 44 Authors: Ms Diane Booth, Chief Pharmacist,. Mrs Kiran Hewitt, Lead Clinical Pharmacist, Berkshire Healthcare NHS Foundation

More information

Calgary Long Term Care Formulary. Pharmacy & Therapeutics. February 2015

Calgary Long Term Care Formulary. Pharmacy & Therapeutics. February 2015 Calgary Long Term Care Formulary Pharmacy & Therapeutics February 2015 Highlights http://www.albertahealthservices.ca/4070.aspx 1 Contents February 2016... 3 Added Product(s)... 3 Not Listed, Delisted

More information

Guidance on the Use of Antipsychotics

Guidance on the Use of Antipsychotics Guidance on the Use of Antipsychotics Version 3 (October 2015) GUIDELINE NO RATIFYING DRUGS AND THERAPEUTICS GROUP COMMITTEE DATE RATIFIED DATE AVAILABLE ON INTRANET NEXT REVIEW DATE October 2017 ORIGINAL

More information

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Effective: July. 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy

More information

National Center for Mental Health

National Center for Mental Health National Center for Mental Health 9 de Febrero St., Mandaluyong City Telephone No.: 531-9001 (c/o Dr. Vinluan) Organizational Structure Medical Center Chief II Chief, Medical and Professional Staff (Hospital

More information

2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview

2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview 2019 STEP THERAPY CRITERIA UCare Individual & Family Plans UCare Individual & Family Plans with Fairview In some cases, UCare requires you to first try certain drugs to treat your medical condition before

More information

DEPOT ANTIPSYCHOTIC MEDICATION: GUIDELINES FOR PRESCRIBING AND ADMINISTERING

DEPOT ANTIPSYCHOTIC MEDICATION: GUIDELINES FOR PRESCRIBING AND ADMINISTERING DEPOT ANTIPSYCHOTIC MEDICATION: GUIDELINES FOR PRESCRIBING AND ADMINISTERING DECEMBER 2016 This policy supersedes all previous policies Policy title Depot Antipsychotic Medication: Guidelines for Prescribing

More information

National Center for Mental Health

National Center for Mental Health National Center for Mental Health 9 de Febrero St., Mandaluyong City Telephone No.: 531-91 Organizational Structure Medical Center Chief II Chief, Medical and Professional Staff (Hospital Service) Chief,

More information

List of changes in Out-Patients Formulary

List of changes in Out-Patients Formulary List of changes in Out-Patients Formulary Change in prescriber criteria Alpha Tocopheryl (Vitamin E) suspension 100mg/mL, tablets 50-150mg, tablets 670mg Atorvastatin tablets Bezafibrate tablets 400mg

More information

MEDICINES FORMULARY JANUARY This version supersedes all previous versions for Medicines Formulary

MEDICINES FORMULARY JANUARY This version supersedes all previous versions for Medicines Formulary EDICIES FORULARY JAUARY 2017 This version supersedes all previous versions for edicines Formulary olicy title edicines Formulary olicy HA05 reference olicy category harmacy Relevant to All staff handling

More information

New Medicines Committee Briefing November 2011

New Medicines Committee Briefing November 2011 New Medicines Committee Briefing November 2011 Paliperidone long-acting injection (Xeplion ) for schizophrenia Paliperidone palmitate long-acting injection (Xeplion ) is to be reviewed for use within:

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium olanzapine 210mg, 300mg, 405mg powder and solvent for prolonged release suspension for injection (ZypAdhera ) No. (624/10) Eli Lilly and Company Limited 09 July 2010 The Scottish

More information

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients

Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Antipsychotics Prior Authorization Criteria for Louisiana Fee for Service and MCO Medicaid Recipients Preferred Agents (Oral) a Amitriptyline/Perphenazine (Generic) Aripiprazole Tablet (Generic) b Chlorpromazine

More information

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY

ALAMEDA COUNTY BEHAVIORAL HEALTH CARE SERVICES MEDICATION FORMULARY ANTIDEPRESSANTS Serotonin Selective Reuptake Inhibitors citalopram 10, 20, 40 mg, 10 mg/5cc $ 0.40 No escitalopram 10, 20 mg $ 2.60 Yes fluoxetine 10, 20 mg, 20 mg/5 ml $ 0.40 Yes fluvoxamine 25, 50, 100

More information

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues

Antipsychotics. Something Old, Something New, Something Used to Treat the Blues Antipsychotics Something Old, Something New, Something Used to Treat the Blues Objectives To provide an overview of the key differences between first and second generation agents To an overview the newer

More information

Bramley Health Formulary March 2016 Review Date March 2017

Bramley Health Formulary March 2016 Review Date March 2017 Bramley Health Formulary March 2016 Review Date March 2017 This provides a formulary for use within Bramley Health. This only relates to psychiatric indications. Some of the medicines listed are also used

More information

Antipsychotic Medications Age and Step Therapy

Antipsychotic Medications Age and Step Therapy Market DC *- Florida Healthy Kids Antipsychotic Medications Age and Step Therapy Override(s) Approval Duration Prior Authorization 1 year Quantity Limit *Virginia Medicaid See State Specific Mandates *Indiana

More information

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds

Hearts and Minds An ECG Update. Tuesday 18 th November The Met Hotel, Leeds Hearts and Minds An ECG Update Tuesday 18 th November The Met Hotel, Leeds Ashleigh Bradley Specialist Clinical Pharmacist for Mental Health and Lithium Clinic Airedale NHS Foundation Trust Introduction

More information

FORMULARY AND PRESCRIBING GUIDANCE

FORMULARY AND PRESCRIBING GUIDANCE FORMULARY AND PRESCRIBING GUIDANCE GUIDELINE VERSION 18 RATIFYING GROUP Drugs and Therapeutics Group (DTG) DATE PUBLISHED NEXT REVIEW DATE (see specific guidelines) FORMULARY SPONSOR Executive Medical

More information

THE STATE HOSPITALS BOARD FOR SCOTLAND ANNUAL REPORT. Medicines Committee. Reference Number

THE STATE HOSPITALS BOARD FOR SCOTLAND ANNUAL REPORT. Medicines Committee. Reference Number THE STATE HOSPITALS BOARD FOR SCOTLAND ANNUAL REPORT Medicines Committee Reference Number Lead Author Contributing Authors Morag Wright Jill Kerr, Clinical Effectiveness Issue: Approval Group Medicines

More information

Resubmission. Scottish Medicines Consortium

Resubmission. Scottish Medicines Consortium Scottish Medicines Consortium Resubmission aripiprazole 5mg, 10mg, 15mg, 0mg tablets; 10mg, 15mg orodispersible tablets; 1mg/mL oral solution (Abilify ) No. (498/08) Bristol-Myers Squibb Pharmaceuticals

More information

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia

Objectives. Epidemiology. Diagnosis 3/27/2013. Identify positive and negative symptoms used for diagnosis of schizophrenia Objectives Identify positive and negative symptoms used for diagnosis of schizophrenia Mohamed Sallout, Pharm D. Pharmacist Resident St. Luke s Magic Valley Regional Medical Center List medications used

More information

Comparison of the Defined Daily Dose and Chlorpromazine Equivalent Methods in Antipsychotic Drug Utilization in Six Asian Countries

Comparison of the Defined Daily Dose and Chlorpromazine Equivalent Methods in Antipsychotic Drug Utilization in Six Asian Countries Research Comparison of the Defined Daily Dose and Chlorpromazine Equivalent Methods in Antipsychotic Drug Utilization in Six Asian Countries Shih-Ku Lin 1,2,, Yen-Feng Lin 1, Shu-Yu Yang 1, Yan-Ling He

More information

CLOZAPINE. Clozapine, (trade name Clopine and Clozaril in Australia) is a second generation atypical antipsychotic agent.

CLOZAPINE. Clozapine, (trade name Clopine and Clozaril in Australia) is a second generation atypical antipsychotic agent. CLOZAPINE Introduction Clozapine, (trade name Clopine and Clozaril in Australia) is a second generation atypical antipsychotic agent. Due to its potential for significant toxicity, it is reserved for patients

More information

Physical health of those with serious mental illness.

Physical health of those with serious mental illness. Physical health of those with serious mental illness. How Compass Health PHO is improving the service for our population Lynley Byrne Clinical Leader Compass Health PHO June 2016 Total Population Compass

More information

Rapid Tranquillisation for adolescent, adults and older people Medicines management team July 2014

Rapid Tranquillisation for adolescent, adults and older people Medicines management team July 2014 Rapid Tranquillisation for adolescent, adults and older people Medicines management team July 2014 A definition of rapid tranquillisation (RT) The use of medicines to quickly control extreme agitation,

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 30 November 2011 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 30 November 2011 List of medicines concerned: SECOND-GENERATION ORAL ANTIPSYCHOTICS SOLIAN 100 mg, 200 mg, 400 mg

More information

Guidance on the Use of Antipsychotic Long-acting Injections in North of England

Guidance on the Use of Antipsychotic Long-acting Injections in North of England Guidance on the Use of Antipsychotic Long-acting Injections in North of England This guidance aims to inform and support prescribers within the three mental health service providers in the north of England

More information

Table of Contents. 1.0 Policy Statement...1

Table of Contents. 1.0 Policy Statement...1 Division of Medical Assistance General Clinical Policy No. A-6 Table of Contents 1.0 Policy Statement...1 2.0 Policy Guidelines...1 2.1 Eligible Recipients...1 2.1.1 General Provisions...1 2.1.2 EPSDT

More information

Proposed Changes to Existing Measure for HEDIS : Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA)

Proposed Changes to Existing Measure for HEDIS : Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) Proposed Changes to Existing Measure for HEDIS 1 2020: Adherence to Antipsychotic Medications for Individuals With Schizophrenia (SAA) NCQA seeks comments on proposed modifications to the HEDIS Health

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Invega Sustenna, Invega Trinza) Reference Number: CP.PHAR.291 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Medicaid See Important Reminder at the end of this policy

More information

Depot Antipsychotics

Depot Antipsychotics Depot Antipsychotics Traffic light classification - Amber 2 Information sheet for Primary Care Healthcare Professionals Scope These guidelines are to support primary care healthcare professionals who are

More information

NSFT Formulary. Double Red Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present.

NSFT Formulary. Double Red Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present. Traffic Light Status NSFT Formulary Not recommended for routine use/not commissioned. These drugs have not been recommended for routine use at present. Hospital/Specialist only Drugs for which the Trust

More information

Guidance on the Use of Antipsychotic Long-acting Injections in North of England (TEWV version)

Guidance on the Use of Antipsychotic Long-acting Injections in North of England (TEWV version) Guidance on the Use of Antipsychotic Long-acting Injections in North of England (TEWV version) This guidance aims to inform and support prescribers within the three mental health service providers in the

More information

Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria

Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Drug/Drug Class Antipsychotics Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization for this clinical criteria Prior

More information

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015)

Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1. Key Points Olanzapine Long-Acting Injection (Zypadhera ) - Guidelines for Prescribing and Administration (Version 3 May 2015) 1.1 Olanzapine long acting injection (LAI) is indicated for the maintenance

More information

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members

IMPORTANT NOTICE. Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members IMPORTANT NOTICE Changes to dispensing of some Behavioral Health Medications for DC Healthcare Alliance members These changes apply only to members covered under the DC Healthcare Alliance program Alliance

More information

Antipsychotics in the treatment of schizophrenia

Antipsychotics in the treatment of schizophrenia Antipsychotics in the treatment of schizophrenia Caroline Parker MRPharmS, MCMHP In the first of a new series of updated articles on the major psychiatric drug groups, produced in association with the

More information

Clinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents

Clinical. High Dose Antipsychotic Prescribing Procedures. Document Control Summary. Contents Clinical High Dose Antipsychotic Prescribing Procedures Document Control Summary Status: Version: Author/Owner/Title: Approved by: Ratified: Related Trust Strategy and/or Strategic Aims Implementation

More information

Rapid Tranquilisation Policy

Rapid Tranquilisation Policy Rapid Tranquilisation Policy Who Should Read This Policy Target Audience All Inpatient Staff Version 1.1 August 2015 Ref. Contents Page 1.0 Introduction 4 2.0 Purpose 4 3.0 Objectives 4 4.0 Process 4 4.1

More information

Schizophrenia. Ajay Karia, Laura Kravitz and Chetan Shah

Schizophrenia. Ajay Karia, Laura Kravitz and Chetan Shah Browse CD s Update archive for CPD help www.chemistanddruggist.co.uk/update Update Your weekly CPD revision guide Module 1523 60-second summary Use this article as part of your CPD to help establish patients

More information

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications

Pharmacy Medical Necessity Guidelines: Antipsychotic Medications Pharmacy Medical Necessity Guidelines: Effective: October 1, 2016 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit

More information

MEDICINES MANAGEMENT TOOL FOR ANTIPSYCHOTICS

MEDICINES MANAGEMENT TOOL FOR ANTIPSYCHOTICS MEDICINES MANAGEMENT TOOL FOR ANTIPSYCHOTICS Document Reference G368 Version Number 4.0 Author/Lead Job Title Wendy Tucker Jackie Stark Alberto Ortiz-Moya Date last reviewed, (this version) August 2017

More information

Psychotropic Medication Utilization in Care Home Residents Age 65 or Older Compared with the Equivalent General Population in Scotland

Psychotropic Medication Utilization in Care Home Residents Age 65 or Older Compared with the Equivalent General Population in Scotland Spring 2013 Psychotropic Medication Utilization in Care Home Residents Age 65 or Older Compared with the Equivalent General Population in Scotland Tyler P. Stewart Martin School of Public Policy and Administration

More information

Slide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts

Slide 1. Slide 2. Slide 3. Risperidone Binding Profile. Risperidone Prescribing Facts. Risperidone Prescribing Facts Slide 1 Risperidone Binding Profile (high affinity for D2 receptors) a 1 antagonist a 2 antagonist Slide 2 Risperidone Prescribing Facts 2 8 mg/day for acute psychosis and bipolar disorder 0.5-2 mg /day

More information

Assessment of physical monitoring following rapid tranquillisation. Stephen Dye

Assessment of physical monitoring following rapid tranquillisation. Stephen Dye Assessment of physical monitoring following rapid tranquillisation Stephen Dye Aims X Lecture on developments in RT Review of recent studies Discussion of specific medications Containment measures Definition

More information

PORT, 2009 Spain, 2009 Malaysia, 2009 Singapore, 2009 BAP, 2011 WFSBP, 2012 SIGN, 2013 Harvard NICE RANZCP, 2016

PORT, 2009 Spain, 2009 Malaysia, 2009 Singapore, 2009 BAP, 2011 WFSBP, 2012 SIGN, 2013 Harvard NICE RANZCP, 2016 Appendix 3. Comparison of recommendations from clinical practice guidelines. Data extracted in relation to key health questions that are relevant to a clinician adopting an algorithmic approach to the

More information

Schizophrenia in Greater Manchester: Audit

Schizophrenia in Greater Manchester: Audit S i G M A Schizophrenia in Greater Manchester: Audit SiGMA Schizophrenia in Greater Manchester: Audit Report 2011-2012 Audit Co-ordinator/ Author of Report: Project Lead Applicants: Darragh Downey, Karen

More information

YES = formulary NO = non-formulary NO BENEFIT = excluded. Beat4 Beat1 Beat 3 Pace2 Beat2 Pace1 Pace3 Pace4 A NO BENEFIT SANDOZ AMITRIPTYLINE 25

YES = formulary NO = non-formulary NO BENEFIT = excluded. Beat4 Beat1 Beat 3 Pace2 Beat2 Pace1 Pace3 Pace4 A NO BENEFIT SANDOZ AMITRIPTYLINE 25 Benefits are subject to the following: Pre-authorisation Bestmed guidelines Bestmed protocols Mediscor Reference Price (MRP) This price represents the reasonable price in the market place for a particular

More information

PULL OUT AND KEEP LEARNING SCENARIOS FOR THIS MODULE AT PHARMACY MAGAZINE

PULL OUT AND KEEP LEARNING SCENARIOS FOR THIS MODULE AT  PHARMACY MAGAZINE magazine CPD MODULE module 226 www.pharmacymag.co.uk WELCOME to the two hundred and twenty sixth module in the Pharmacy Magazine Continuing Professional Development Programme, which looks at current thinking

More information

West London Mental Health NHS Trust Formulary

West London Mental Health NHS Trust Formulary West London Mental Health NHS Trust Formulary VERSION 3.0 (18.02.15) The Formulary is a list of medicines used for mental health indications for patients cared for in all settings of West London Mental

More information

FORMULARY AND PRESCRIBING GUIDANCE

FORMULARY AND PRESCRIBING GUIDANCE FORMULARY AND PRESCRIBING GUIDANCE GUIDELINE VERSION 13 RATIFYING GROUP Drugs and Therapeutics Group (DTG) DATE PUBLISHED August 2014 NEXT REVIEW DATE (see specific guidelines) FORMULARY SPONSOR Executive

More information

Antipsychotics by Cayte Hoppner (updated by Glenice Bateman, Pharmacist, 2011)

Antipsychotics by Cayte Hoppner (updated by Glenice Bateman, Pharmacist, 2011) Antipsychotics by Cayte Hoppner (updated by Glenice Bateman, Pharmacist, 2011) Introduction Antipsychotics are the foundation of pharmacological treatment of schizophrenia and other psychotic illnesses.

More information

Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents

Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents Criteria for Child Psychiatrist on the Use of Selected Psychotropic Medications in Children & Adolescents DRUG NAME INDICATIONS / ACCEPTABLE USES PRIOR STIMULANT/ADHD DRUGS Daytrana (methylphenidate) ADHD

More information

Method. NeuRA First versus second generation antipsychotics August 2016

Method. NeuRA First versus second generation antipsychotics August 2016 Introduction First generation typical are an older class of antipsychotic than second generation atypical. First generation are used primarily to treat positive symptoms including the experiences of perceptual

More information

West London Mental Health NHS Trust Formulary

West London Mental Health NHS Trust Formulary West London Mental Health NHS Trust Formulary VERSION 7.0 (09.11.16) The Formulary is a list of medicines used for mental health indications for patients cared for in all settings of West London Mental

More information